KUEHNE UND NAGEL INTERNATIONAL AG - Successfully delivered its first Sinovac Covid-19 vaccine shipment to Thailand
- Kuehne+Nagel Thailand ready to support private sector with the import of the Covid-19 vaccine
Kuehne+Nagel has successfully delivered its first 500,000 doses of Covid-19 vaccine produced by Sinovac Biotech Ltd., a leading biopharmaceutical company in China (Nasdaq: SVA) to Bangkok, Thailand.
The shipment is part of a global agreement between the two companies. The 500,000 doses of Covid-19 vaccine arrived in Bangkok by air transport from Beijing in special active cooling containers. The team adhered to the strict temperature requirement of +2 to +8°C, ensuring the integrity of the product.
'We are proud to be part of Thailand's fight against the pandemic by delivering vaccines to the citizens timely and in compliance with the required temperature control. In line with the Thai government's vaccination strategy, we are ready to support the private sector with the import of the vaccines,' says Sataporn Tanachaisak, National Air Logistics Manager, Kuehne+Nagel Thailand.
Kuehne+Nagel's global KN PharmaChain network covers almost 250 GxP-certified operations having more than 3,500 GxP trained staff members dedicated to the pharmaceutical industry worldwide. In Asia Pacific alone, more than 44 GxP stations are well-established.
About Kuehne+NagelWith 72,500 employees at 1,400 locations in over 100 countries, the Kuehne+Nagel Group is one of the world's leading logistics companies. Its strong market position lies in sea logistics, air logistics, road logistics and contract logistics, with a clear focus on integrated logistics solutions.
Attachments
- Original document
- Permalink
Disclaimer
Kuehne + Nagel International AG published this content on 27 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2021 03:02:00 UTC.
